| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Departments of Medicine and Pharmacology, The Cancer Institute of New Jersey [J. Y., J-M. Y., M. I., W. N. H.] and School of Public Health [W. J. S., Y. L.], New Brunswick, New Jersey, 08901
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Activation of tyrosine kinases through receptor occupation or mutation initiates several signal transduction pathways that culminate in cell division. The epidermal growth factor receptor is frequently overexpressed or mutated in human glioblastoma (3, 4, 5) . Activation of phospholipase C by the epidermal growth factor receptor produces two second messengers, diacylglycerol and inositol-1,4,5-triphosphate. Whereas the former can participate in mitogen-activated protein kinase signaling, the latter activates calmodulin-dependent pathways through the release of intracellular calcium (6, 7, 8, 9) .
We previously found that calmodulin-dependent phosphorylation of eEF-23 was markedly increased in glioblastoma because of the increased activity of calmodulin-dependent protein kinase 3 (10) , also known as EF-2 kinase (11, 12, 13) . EF-2 kinase phosphorylates eEF-2 in response to elevation in intracellular calcium, which leads to the inactivation of this translation factor (14 , 15) . Additional studies defined EF-2 kinase as a proliferation-dependent and mitogen-activated enzyme in a variety of normal and malignant cell types (16 , 17) .
The cloning and sequencing of EF-2 kinase led to the realization that it represented a unique enzyme family (13) . Except for the ATP binding site, EF-2 kinases from several different species exhibit no sequence homology to any Ca2+/calmodulin-dependent protein kinase, or to any member of the eukaryotic protein kinase superfamily. However, EF-2 kinase does have homology to the catalytic domain of myosin heavy chain kinase A (MHCK A) from Dictyostelium. The unique structural features of EF-2 kinase, together with its increased activity in malignancy and cell-cycle dependency, makes it a novel target for anticancer therapies.
In fact, several lines of evidence suggest that inhibiting the activity of EF-2 kinase can kill cancer cells. For example, Parmer et al. (18) , demonstrated that rottlerin, an EF-2 kinase inhibitor, blocked glioma cells at the G1-S phase interface and killed a variety of cell lines at concentrations (1–10 nM) that were consistent with IC50s for enzyme inhibition (18) . Antisense RNA to calmodulin (19) and EF-2 kinase4 markedly decreased the clonogenicity of rat and human glioma cell lines. Therefore, identification of new drugs that block the function of EF-2 kinase may lead to new types of anticancer drugs.
During the purification of EF-2 kinase (20) , we found the enzyme to be tightly associated with Hsp90 as previously demonstrated by Palmquist et al. (21) . Hsp90 is a protein chaperone responsible for maintaining proper protein folding and stability (22) . Recently, a new class of drug, the GAs was found to disrupt Hsp90/protein interactions (23) . These benzoquinone ansamycin antibiotics were shown to have antitumor effects in cell culture and experimental animals (24) . Recently, 17-AAG, a less toxic and less potent derivative of GA, has entered Phase I clinical testing (25, 26, 27) .
Because the activity of EF-2 kinase is markedly increased in human glioblastoma and is chaperoned by Hsp90, we examined the effects of the GAs on this lethal malignancy of the central nervous system.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Drugs.
GA and 17AAG were obtained from Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis of the National Cancer Institute in the form of a lyophilized powder. They were stored in dark, airtight containers at 4°C and reconstituted in DMSO immediately before use.
Clonogenic Assays.
Cytotoxicity of GA and 17AAG was determined by clonogenic assay. Four x 102 C6 cells or 6 x 102 T98G cells were plated in 60-mm tissue culture dishes and allowed to adhere overnight. The cells were then exposed to various concentrations of drug ranging from 0.05–100 nM (control cultures were treated with 0.01% DMSO) and incubated for 24–48 h at 37°C. The medium was then removed and replaced with fresh medium free of drug. After 7–10 days of growth, colonies were fixed and stained with 0.5% methylene blue. Colonies with diameters of 2 mm and larger were counted using an electronic counting pencil.
Preparation of Cell Homogenates for Detection of Cellular EF-2 Kinase.
Cell monolayers were washed twice in PBS (pH 7.4), scraped into 15-ml centrifuge tubes in 5 ml of PBS, and then centrifuged at 1,000 x g for 5 min. Cell pellets were homogenized with 15 strokes in ice-cold HOMO buffer [25 mM HEPES (pH 7.4), 100 mM sodium chloride, 20 mM sodium PPi, 2 mM EDTA, 0.1 mM PMSF, 10 µg/ml leupeptin, 2 µg/ml pepstatin A, and 0.1 mM sodium orthovanadate], using a Polytron homogenizer. The homogenates were then centrifuged at 15,000 x g for 30 min at 4°C. The protein concentration of the supernatants was determined according to the method of Bradford using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Richmond, CA). Twenty µg of protein from each sample were used for EF-2 kinase detection. Sample volumes were adjusted with HOMO buffer. Samples were boiled with 3x Laemmli buffer [190 mM Tris (pH 6.8), 6% SDS, 30% glycerol, 15% 2-mercaptoethanol, and 0.003% bromphenol blue dye] for 5 min before resolution by 7.5% SDS-PAGE.
Immunoprecipitations.
Cell monolayers were washed twice with PBS and lysed with NET lysis buffer [50 mM Tris-HCl (pH7.4), 150 mM NaCl, 0.1% NP40, 1.0 mM EDTA, 1 mM PMSF, and 1% aprotinin] at 4°C for 30 min. Cells were scraped into 1.5-ml microcentrifuge tubes and incubated at 4°C with rotation for 30 min, passed through a 25-gauge needle, and then centrifuged at 15,000 x g at 4°C for 30 min. The protein concentration of the supernatants was determined using the Bio-Rad protein assay kit.
Immunoprecipitations were performed using 2 mg (C6 cells) or 1 mg (T98G cells) of protein from total cell lysates as starting material. Reaction volumes were equalized using NET buffer. For Hsp90 precipitation, 4 µg of anti-Hsp90 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) were added to each sample. For EF-2 kinase precipitation, 4 µl of anti-EF-2 kinase rabbit serum (kindly provided by Dr. A. C. Nairn of Rockefeller University, New York, NY) was used. Immunoprecipitation of samples with preimmune sera was used as a control. After 1–4 h of rotating incubation at 4°C, 80 µl of Protein A-Sepharose CL-4G (50% NET buffer; Amersham Pharmacia Biotech, Piscataway, NJ) were added. Tubes were incubated overnight at 4°C with rotation. At the end of the incubation, samples were centrifuged at 15,000 x g at 4°C for 2 min, and the supernatant was discarded. Beads were washed twice with NET buffer and twice with PBS containing 1% aprotinin and 1 mM PMSF. After the final wash, 30 µl of Laemmli buffer were added, and the samples were boiled for 5 min. After a 3-min spin at 15,000 x g, supernatants were loaded onto a 8% SDS-PAGE gel.
Western Blot Analysis.
Proteins resolved on SDS-PAGE were transferred to nitrocellulose membranes (Hybond ECL; Amersham Pharmacia Biotech). Membranes were first blocked with 10% milk in PBS-T (PBS/0.1% Tween) and then were incubated with anti-EF-2 kinase rabbit antiserum in 10% milk/PBS-T for EF-2 kinase detection. For detection of Hsp90, the anti-Hsp90 rabbit antiserum was used. An anti-ß-actin monoclonal mouse ascites (Sigma Chemical Co., St. Louis, MO) was used for detection of ß-actin. After a 2-h incubation with the primary antibodies, membranes were washed in PBS-T, incubated with horseradish peroxidase conjugated secondary antibodies (Amersham-Life Science), and washed again with PBS-T. Mr standards (Bio-Rad Laboratories, Richmond, CA) and authentic EF-2 kinase were used to determine the position of the proteins of interest. Proteins were visualized using Amersham-Pharmacia ECL detection reagents. Blots were scanned by UMAX Magic Scan 4.3 program, and the intensity of protein bands was quantified by Molecular Analyst software.
Generation of Stable Cell Lines Expressing Different Levels of EF-2 Kinase.
pSTAR vector was originally constructed to mediate tetracycline-induced gene expression in mammalian cells (28)
. However, this vector conferred constitutive expression of target genes in most stable clones that we have tested, which was likely attributable to the use of two strong promoters, cytomegalovirus and SV40, in this vector system. A full-length human EF-2 kinase cDNA was inserted into the multiple cloning site region of pSTAR in both antisense (AS) and sense (S) orientations. Constructs expressing AS (pJYH1) and sense (pJYH2) EF-2 kinase mRNA were introduced into T98G human glioma cells by liposome-mediated transfection (Life Technologies, Inc., Rockville, MD). Transfectants were selected in 500 µg/ml G418. G418-resistant colonies were expanded and maintained in 200 µg/ml G418. Cytosolic extracts of each clone were collected by homogenization and centrifugation and were analyzed for EF-2 kinase expression by Western blot. The TJY1-R clone was found to express low amounts of EF-2 kinase protein. The TJY2-D clone expressed high levels of sense EF-2 kinase mRNA and protein compared with that of TJY1-R.
Treatment of Glioma Xenografts with 17-AAG.
C6 cells grown at logarithmic phase were removed from culture flasks by trypsinization, then washed and resuspended in PBS at density of 1.6 x 107 cells/ml. Cells (1.6 x 106/100 µl) were injected into the flank of each of 16 Swiss nude (nu/nu) mice (male, 5 weeks old; Taconic, Germantown, NY). The s.c. grown tumors were measured daily with a Vernier caliper. The length (L) and width (W; in mm) of the tumors were taken and used to calculate the volume (V), using the formula: 
. On the 12th day after inoculation, when the median tumor volume reached 60 mm3, the mice were paired by the similarity of the tumor volumes. Within each pair, mice were randomly assigned to either 17-AAG or vehicle. Animals received i.p. injections of 17-AAG (80 mg/kg) or vehicle on days 2, 3, 4, 5, and 8, 9, 10, 11, and 12.
Statistical Analysis.
The two-sample t test was used to compare tumor volumes between the two treatment groups at treatment day 1. Logs(tumor volume) on day 5 to day 22 were analyzed using the repeated-measurement model with treatment and day as factors and the first order autoregressive correlation structure (29)
.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Table 1
). GA also inhibited the clonogenicity of the C6 rat glioma line (IC50, 1.5 nM).
|
|
10-fold less potent than GA against the same cell lines. IC50 value for C6 cells was 13 nM and for T98G cells was 35 nM (Fig. 1B
; Table 1
).
For comparison, we also performed clonogenic assays of C6 cells treated with BCNU, a standard chemotherapeutic drug used to treat glioblastoma. Fig. 1C
and Table 1
show that the IC50 of BCNU against C6 cells was 5 µM, 3000-fold greater than the IC50 value of GA against the same cell line.
Effect of GA and 17-AAG on EF-2 Kinase Protein Content.
To analyze the role of EF-2 kinase in the cytotoxicity of GAs, we tested whether or not GA or 17-AAG affected EF-2 kinase content in glioma cells. T98G cells were incubated with 0–40 nM GA for 24 h (Fig. 2A
, left panel). Cell homogenates were collected and EF-2 kinase measured by Western blot. Fig. 2
demonstrates that there was a >50% decrease in EF-2 kinase at a concentration of 10 nM and a >80% decrease after treatment with 20 nM GA. We chose the 24-h incubation time to avoid problems in interpretation of data obtained using a dying population of cells (Fig. 1)
. Similar results were observed in C6 cells treated with GA for 24 h (Fig. 2B)
; EF-2 kinase was reduced by 70% after treatment with 1–10 nM GA. 17-AAG (20–40 nM) decreased EF-2 kinase by 40–50% (Fig. 2A
, right panel).
|
and C6 cells (Fig. 3B)
were treated with 10 nM GA, 40 nM 17-AAG, or vehicle (0.1% DMSO) for 24 h (the optimal conditions for reducing the cellular content of EF-2 kinase as shown above). Cell lysates were incubated with anti-Hsp90 rabbit antiserum or preimmune serum and protein-A beads to immunoprecipitate Hsp90. After Western transfer, the membranes were first blotted with anti-EF-2 kinase polyclonal antibody and then were stripped and reblotted with anti-Hsp 90 polyclonal antibody. Fig. 3, A and B
, demonstrate that approximately equal amounts of Hsp90 (bottom panels) were precipitated under each condition. EF-2 kinase (upper panels) was coprecipitated with Hsp90 in vehicle-treated cells (Lane 1) but not with preimmune serum (data not shown), which confirmed the association of the kinase with Hsp90 in both T98G and C6 cells. Treatment with GA (Lane 2) or 17-AAG (Lane 3) significantly reduced the amount of EF-2 kinase that was coprecipitated with Hsp90 in both cell lines.
|
demonstrates that the amount of EF-2 kinase in T98G or C6 cells was not significantly changed under these conditions. The amount of EF-2 kinase that was coimmunoprecipitated with Hsp90 under these conditions was markedly decreased (Fig. 3, A and B
, Lanes 4 and 5).
We next determined whether antibodies to EF-2 kinase could immunoprecipitate Hsp90 and whether GA disrupted the interaction. Immunoprecipitation was performed using an anti-EF-2 kinase antibody and cell lysates from T98G and C6 were treated with either vehicle or 3 µM GA for 3 h (Fig. 4)
. Similar amounts of EF-2 kinase were recovered under each condition (lower panel). Hsp90 was coprecipitated with EF-2 kinase in vehicle controls (Lanes 1 and 3) but was absent in the immune-complex from GA-treated cell lysates (Lanes 2 and 4).
|
shows that TJY2-D cells express 6-fold more EF-2 kinase protein as compared with that of TJY1-R cells.
|
and Table 1
demonstrate that cells that overexpress EF-2 kinase were 5-fold less sensitive to the cytotoxic effects of GA (IC50, 2 nM) than isogenic cells with less EF-2 kinase content (IC50, 0.4 nM).
Effect of 17-AAG on Glioma Growth in Mice.
To test whether GAs remained active against glioma cell lines in vivo, we evaluated the effect of 17-AAG on the growth of C6 glioma cells in nude mice. C6 cells were implanted in sixteen mice in the dorsal flank; tumors were allowed to form for 12 days and reached 60 mm3 in size before treatment began. Fig. 6
demonstrates the ability of 17-AAG to significantly inhibit the growth of C6 glioma. The mean tumor volumes of the two treatment groups were not statistically different before drug treatment (day 1; P > 0.752). The differences in tumor volumes between the two treatment groups were statistically significant (P 
0.017) at all time points from day 5 to day 22 [least-square means of log(tumor volume), 0.91 ± 0.33 (mean ± SE)]. No significant weight loss, changes in activity or deaths were observed during the period of drug treatment.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Disruption of Hsp90 chaperoning represents a novel approach to developing new anticancer therapies. Numerous proteins induced in the growth of malignant cells associate with Hsp90 (22 , 33) . Interference with this interaction targets the nonassociated protein for degradation (34, 35, 36, 37, 38) . Therefore, it may be possible to target proteins important for the growth of malignant cells by disrupting their association with Hsp90.
EF-2 kinase is an attractive target for the treatment of high-grade astrocytomas and perhaps other malignancies. The markedly increased activity of this enzyme in glioblastoma multiforme (17) and the cytotoxicity of specific and nonspecific inhibitors for this kinase support this concept (18) . Because EF-2 kinase is chaperoned by Hsp90 (20 , 21) , we examined the effects of GAs on glioma and other malignant cell lines of neurogenic origin and found these drugs to be potent cytotoxic agents that disrupt Hsp90/EF-2 kinase interactions.
GA is a potent inhibitor of the clonogenicity of several cell lines including T98G and C6 glioblastoma, Daoy medulloblastoma, and SKNSH neuroblastoma (Fig. 1)
. Table 1
lists the IC50 values obtained after a 48-h exposure to GA that ranged from 1 to 3 nM. For C6 cells, GA is 2500 times more potent than BCNU, a standard chemotherapy for glioblastoma (39, 40, 41, 42)
. 17-AAG, a less potent inhibitor of Hsp90/protein interactions (25
, 26) compared with GA, is also a less potent inhibitor of clonogenicity in T98G and C6 cells, with IC50 values ranging from 13 to 35 nM (Fig. 1
; Table 1
). It is nevertheless a potent compound when compared with BCNU.
To determine whether or not the cytotoxicity of GAs was attributable, at least in part, to inhibition of EF-2 kinase activity through disruption of Hsp90 chaperoning, we carried out a series of experiments to measure both the association and depletion of the enzyme. These studies revealed a good correlation between the concentration of drug required to disrupt Hsp90/EF-2 kinase interactions and effects on clonogenic survival. For example, after a 24 h incubation of T98G cells with 10 nM GA there is a >50% decrease in EF-2 kinase (Fig. 2A)
, which correlates with the IC50 of 3 nM obtained by clonogenic assay after exposing the cells to drug for 48 h (Fig. 1
; Table 1
).We chose the shorter incubation period to evaluate the effect of drug exposure on kinase degradation to avoid the pitfalls of studying the effects of drug in a population in which one-half the cells were dead or dying. Similarly, we found a 70% decrease in EF-2 kinase in C6 cells exposed for 24 h to 10 nM GA, which correlates with the IC50 value of 2 nM obtained by clonogenic assay after exposing the cells to drug for 48 h. The IC50s in clonogenic assays for 17-AAG were 5- to 10-fold greater than those of GA, which correlates to the decreased potency of this derivative in producing loss of the kinase (Fig. 2A)
.
Interference with the chaperoning function of Hsp90 is known to be detrimental to associated kinases. GA disrupts the binding of EF-2 kinase to Hsp90 as measured by coimmunoprecipitation (Fig. 3
and 4
). The disruption of this interaction is associated with decreased EF-2 kinase protein content (Fig. 2)
. Schulte et al., demonstrated that the serine/threonine kinase, raf-1, is rapidly destabilized on addition of GA, which disrupts the Raf-1/Hsp90 molecular complex (38)
. The disappearance of EF-2 kinase in glioma cells treated with GA is likely caused by this mechanism. These data are consistent with a proposed mechanism by which GAs disrupt the chaperoning of critical cellular proteins leading to targeted degradation (38
, 43
, 44)
. Further insight may be gained by investigating the mechanism by which the EF-2 kinase protein is degraded. Published reports (45, 46, 47)
point toward the role of GA in targeting proteins for proteosome degradation.
GAs are likely to affect numerous intracellular targets that are critical for cell viability. In addition to raf-1 (26
, 48, 49, 50)
, both GA and 17-AAG deplete cells of the transmembrane protein tyrosine kinase p185erB-2, which has been implicated in oncogenic transformation (45
, 51)
. Treatment of lung cancer cell lines expressing p185 with paclitaxel and 17-AAG showed synergistic activity (52)
. 17-AAG also destabilizes mutant forms of p53 (47)
. Therefore, to understand the importance of EF-2 kinase among these other targets, we transfected parental T98G cells with either sense or antisense EF-2 kinase expression vectors. As expected, overexpression of antisense mRNA and subsequent decrease in EF-2 kinase (Fig. 5A)
reduced the viability and subsequent recovery of transfected clones (53)
. Nonetheless, we were able to study drug sensitivity by choosing our most robust antisense clone for these experiments and compared this with a sense clone obtained during the same round of transfections. We then chose a shorter drug exposure time (24 h) to measure effects on clonogenicity and repeatedly found the antisense clone to be more sensitive to GA (Fig. 5B)
. This result is consistent with EF-2 kinase being an important target for the cytotoxicity of GAs in glioma cell lines. However, despite the excellent correlation between EF-2-kinase content and drug sensitivity (Fig. 5, A and B)
, given the difficulty in recovering viable antisense clones, we cannot rule out the possibility that these are indirect effects resulting from clonal selection.
Numerous drugs kill cancer cells in tissue culture but far fewer retain activity in animal xenografts. We studied 17-AAG against xenografted C6 glioma because it is a less toxic compound that has already entered clinical testing (26
, 27)
. 17-AAG significantly inhibits the growth of established gliomas in animals. Treatment that is started after 12 days of growth significantly inhibits the growth of the xenografts (Fig. 6)
. This is particularly promising because the drug is highly lipid-soluble and likely to penetrate the blood-brain barrier.
In summary, our results demonstrate that GAs represent a new class of anticancer drug that have potent activity against glioblastoma and other malignant cell lines of neurogenic origin. The compounds disrupt the interaction of EF-2 kinase with Hsp90, leading to the destruction of this unique protein kinase member of the calmodulin-mediated pathway of signal transduction.
|
FOOTNOTES |
|---|
1 Supported by USPHS Grant CA43888 and National Cancer Institute (NIH) Grant CA72720. 
2 To whom requests for reprints should be addressed, at The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey 08901. Phone: (732) 235-8064; Fax: (732) 235-8094; E-mail: haitwn{at}umdnj.edu
3 The abbreviations used are: eEF-2, elongation factor 2; EF-2 kinase, elongation factor 2 kinase; 17-AAG, 17-allylamino-17-demethoxygeldanamycin; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; GA, geldanamycin; Hsp90, heat shock protein 90; PMSF, phenylmethylsulphonyl fluoride.
4 S. Hua, J. Yang, and W. N. Hait, unpublished observations.
Received 10/ 6/00. Accepted 3/16/01.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
B activation. J. Biol. Chem., 275: 10519-10526, 2000.This article has been cited by other articles:
|
|
 |
|
  C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells Neuro-oncol, January 1, 2009; 11(2): 109 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Castorena, S. A. Weeks, K. A. Stapleford, A. M. Cadwallader, and D. J. Miller A Functional Heat Shock Protein 90 Chaperone Is Essential for Efficient Flock House Virus RNA Polymerase Synthesis in Drosophila Cells J. Virol., August 15, 2007; 81(16): 8412 - 8420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Weigel, S. M. Blaney, J. M. Reid, S. L. Safgren, R. Bagatell, J. Kersey, J. P. Neglia, S. P. Ivy, A. M. Ingle, L. Whitesell, et al. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study Clin. Cancer Res., March 15, 2007; 13(6): 1789 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Nowakowski, A. K. McCollum, M. M. Ames, S. J. Mandrekar, J. M. Reid, A. A. Adjei, D. O. Toft, S. L. Safgren, and C. Erlichman A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6087 - 6093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wu, J.-M. Yang, S. Jin, H. Zhang, and W. N. Hait Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res., March 15, 2006; 66(6): 3015 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Graner and D. D. Bigner Chaperone proteins and brain tumors: Potential targets and possible therapeutics Neuro-oncol, July 1, 2005; 7(3): 260 - 278. [Abstract] [PDF]
|
|
|
|
|
|
S. Arora, J.-M. Yang, and W. N. Hait Identification of the Ubiquitin-Proteasome Pathway in the Regulation of the Stability of Eukaryotic Elongation Factor-2 Kinase Cancer Res., May 1, 2005; 65(9): 3806 - 3810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nobukuni, K. Kohno, and K. Miyagawa Gene Trap Mutagenesis-based Forward Genetic Approach Reveals That the Tumor Suppressor OVCA1 Is a Component of the Biosynthetic Pathway of Diphthamide on Elongation Factor 2 J. Biol. Chem., March 18, 2005; 280(11): 10572 - 10577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Goetz, D. Toft, J. Reid, M. Ames, B. Stensgard, S. Safgren, A. A. Adjei, J. Sloan, P. Atherton, V. Vasile, et al. Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer J. Clin. Oncol., February 20, 2005; 23(6): 1078 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Arora, J.-M. Yang, R. Utsumi, T. Okamoto, T. Kitayama, and W. N. Hait P-Glycoprotein Mediates Resistance to Histidine Kinase Inhibitors Mol. Pharmacol., September 1, 2004; 66(3): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Arora, J.-M. Yang, T. G. Kinzy, R. Utsumi, T. Okamoto, T. Kitayama, P. A. Ortiz, and W. N. Hait Identification and Characterization of an Inhibitor of Eukaryotic Elongation Factor 2 Kinase against Human Cancer Cell Lines Cancer Res., October 15, 2003; 63(20): 6894 - 6899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Russell, W. Burgan, K. A. Oswald, K. Camphausen, and P. J. Tofilon Enhanced Cell Killing Induced by the Combination of Radiation and the Heat Shock Protein 90 Inhibitor 17-Allylamino-17- Demethoxygeldanamycin: A Multitarget Approach to Radiosensitization Clin. Cancer Res., September 1, 2003; 9(10): 3749 - 3755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Vasilevskaya, T. V. Rakitina, and P. J. O'Dwyer Geldanamycin and its 17-Allylamino-17-Demethoxy Analogue Antagonize the Action of Cisplatin in Human Colon Adenocarcinoma Cells: Differential Caspase Activation as a Basis for Interaction Cancer Res., June 15, 2003; 63(12): 3241 - 3246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Pratt and D. O. Toft Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery Experimental Biology and Medicine, February 1, 2003; 228(2): 111 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Jones, E Aird, H Colyer, J Dobbs, R Harris, P Hoskin, A Mckenzie, and C West United Kingdom Radiation Oncology 1 Conference (UKRO 1): Accuracy and uncertainty in radiotherapy Br. J. Radiol., April 1, 2002; 75(892): 297 - 306. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-L. Xu, D. L. Feinstein, R. A. Santizo, H. M. Koenig, and D. A. Pelligrino Agonist-specific differences in mechanisms mediating eNOS-dependent pial arteriolar dilation in rats Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H237 - H243. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
